Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY20 results · Jan–Mar 2020
Neuland Laboratories reported revenue from operations of ₹191.64 crore and net loss of ₹9.30 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 191.64 | 0.00 | — | 203.84 | −6.0% |
| Other income | 1.78 | 0.00 | — | 1.02 | +73.7% |
| Total income | 193.42 | 0.00 | — | 204.87 | −5.6% |
| Profit before tax | 17.20 | 0.00 | — | 15.67 | +9.7% |
| Net profit for the period | (9.30) | 0.00 | — | 11.11 | Turned loss |
| EPS, basic (₹) | (7.25) | 0.00 | — | 8.66 | Turned loss |
| Net margin (%) | -4.9 | — | 5.5 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 191.87 | 172.66 | +11.1% | 203.62 | −5.8% |
| Other income | 1.78 | 1.33 | +33.1% | 1.02 | +73.7% |
| Total income | 193.64 | 174.00 | +11.3% | 204.64 | −5.4% |
| Profit before tax | 17.08 | 8.09 | +111.1% | 15.57 | +9.6% |
| Net profit for the period | (9.35) | 6.73 | Turned loss | 11.04 | Turned loss |
| EPS, basic (₹) | (7.29) | 5.25 | Turned loss | 8.61 | Turned loss |
| Net margin (%) | -4.9 | 3.9 | 5.4 |
Consolidated
- Filed with BSE
- 23 May 2020, 10:07 IST
- Board meeting
- 22 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 May 2020, 10:07 IST
- Board meeting
- 22 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE